ESN-X / Enveda Biosci - LARVOL DELTA

Enveda Biosciences Named One of Biotech’s Most Promising Startups by Endpoints News (Businesswire) - "Enveda’s platform and library has already yielded four development candidates, with three additional candidates in fast follow. The two lead compounds both target inflammation. The first addresses inflammatory bowel disease through a novel MOA and biodistribution. The second, addressing atopic dermatitis, inhibits neutrophil migration through a unique MOA, blocking multiple chemoattractant pathways with a single molecule. Both of these compounds are slated to enter clinical trials in 2024."

New trial • Atopic Dermatitis • Immunology • Inflammatory Bowel Disease